Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer

Abstract Background The epidermal growth factor receptor (EGFR) mutation is a risk factor associated with brain metastases (BMs) in patients with non‐small cell lung cancer (NSCLC). This study aimed to evaluate the impact of osimertinib early dose reduction on BM worsening. Methods We retrospectivel...

Full description

Bibliographic Details
Main Authors: Takehiro Tozuka, Rintaro Noro, Akihiko Miyanaga, Shinji Nakamichi, Susumu Takeuchi, Masaru Matsumoto, Kaoru Kubota, Kazuo Kasahara, Masahiro Seike
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Cancer Medicine
Subjects:
brain metastases
dose reduction
non‐small cell lung cancer
osimertinib
Online Access:https://doi.org/10.1002/cam4.6393

Internet

https://doi.org/10.1002/cam4.6393

Similar Items